Eli Lilly's drug candidate donanemab may soon be the third anti-amyloid monoclonal antibody to receive FDA approval, despite slower clinical uptake due to moderate benefits, motivating scientists to find new ways to tackle Alzheimer's.
Clinical trial data shows donanemab can slow cognitive decline by about a third, indicating its potential to make a difference for some patients.
While Alzheimer's drugs like donanemab offer hope, there is still a hunt for more effective treatments, with 127 drugs in 164 clinical trials being assessed against Alzheimer's as of January.
[
Collection
]
[
|
...
]